Supernus Pharmaceuticals Inc  

(Public, NASDAQ:SUPN)   Watch this stock  
Find more results for William M. Vaughn, III.�
+0.02 (0.23%)
Dec 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.65 - 8.78
52 week 6.52 - 11.47
Open 8.72
Vol / Avg. 0.00/459,127.00
Mkt cap 375.64M
P/E     -
Div/yield     -
EPS -0.39
Shares 42.93M
Beta     -
Inst. own 87%
Mar 10, 2015
Q4 2014 Supernus Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Dec 3, 2014
Supernus Pharmaceuticals Inc at Piper Jaffray Healthcare Conference
Nov 18, 2014
Supernus Pharmaceuticals Inc at Stifel Healthcare Conference
Nov 12, 2014
Q3 2014 Supernus Pharmaceuticals Inc Earnings Call
Nov 11, 2014
Q3 2014 Supernus Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 53.07% -767.73%
Operating margin 53.93% -594.64%
EBITD margin - -509.01%
Return on average assets 101.34% -90.03%
Return on average equity 224.63% -202.72%
Employees 235 -
CDP Score - -


1550 East Gude Drive
United States - Map
+1-301-8382500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Supernus Pharmaceuticals, Inc. (Supernus) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Supernus is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder (ADHD). Supernus�s two epilepsy product candidates are SPN-538 and Epliga. Epliga is in Phase III clinical trials. Supernus ADHD product candidates include SPN-810 (molindone hydrochloride), a treatment for impulsive aggression in patients with ADHD, and SPN-812, a non-stimulant treatment for ADHD. Both of these programs are in Phase II. In addition to these four products candidates, Supernus has several additional product candidates in various stages of development, including SPN-809. Its wholly owned subsidiary includes TCD Royalty Sub LLC.

Officers and directors

M. James Barrett Ph.D. Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Jack A. Khattar President, Chief Executive Officer, Secretary, Director
Age: 52
Bio & Compensation  - Reuters
Gregory S. Patrick Chief Financial Officer, Vice President
Age: 56
Bio & Compensation  - Reuters
Stefan K.F. Schwabe M.D., Ph.D. Executive Vice-President - Research & Development, Chief Medical Officer
Age: 62
Bio & Compensation  - Reuters
Padmanabh P. Bhatt Ph.D., Senior Vice President- Intellectual Property, Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
Victor Vaughn Senior Vice President - Sales
Age: 55
Bio & Compensation  - Reuters
Jones W. Bryan Ph.D. Vice President - Business Development
Age: 49
Bio & Compensation  - Reuters
Frederick M. Hudson CPA., Independent Director
Age: 68
Bio & Compensation  - Reuters
Charles W. Newhall III Independent Director
Age: 69
Bio & Compensation  - Reuters
William A. Nuerge Independent Director
Age: 61
Bio & Compensation  - Reuters